Thomas A. MCCOURT - Jan 5, 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Jan 5, 2023
Transactions value $
-$46,604
Form type
4
Date filed
1/9/2023, 03:05 PM
Previous filing
Oct 5, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Options Exercise $1.29M +111K +15.57% $11.65 823K Jan 5, 2023 Direct
transaction IRWD Class A Common Stock Sale -$1.34M -111K -13.48% $12.07 712K Jan 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRWD Employee Stock Options (Right to Buy) Options Exercise $0 -111K -100% $0.00* 0 Jan 5, 2023 Class A Common Stock 111K $11.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The options, vested as to 1.25% on each monthly anniversary of the vesting commencement date for the first 36 months, and as to 4.5833% of the award on each monthly anniversary thereafter, are presently exercisable in full.